These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17596671)

  • 21. Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.
    Lee S; Kim JM; Chung CS; Cho KJ; Kim JH
    Arch Pharm Res; 2003 Nov; 26(11):967-72. PubMed ID: 14661864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
    Gulseth MP; Grice GR; Dager WE
    Am J Health Syst Pharm; 2009 Jan; 66(2):123-33. PubMed ID: 19139476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2C9 genetic polymorphisms and warfarin.
    Redman AR; Dickmann LJ; Kidd RS; Goldstein JA; Ritchie DM; Hon YY
    Clin Appl Thromb Hemost; 2004 Apr; 10(2):149-54. PubMed ID: 15094935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
    Siddiqi A; Khan DA; Khan FA; Naveed AK
    Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
    McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
    Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotype-guided dosing of warfarin.
    Mega JL; Giugliano RP
    Clin Chem; 2014 Jul; 60(7):920-2. PubMed ID: 24691686
    [No Abstract]   [Full Text] [Related]  

  • 28. Warfarin initiation and the potential role of genomic-guided dosing.
    Lee CR
    Clin Med Res; 2005 Nov; 3(4):205-6. PubMed ID: 16303884
    [No Abstract]   [Full Text] [Related]  

  • 29. Possible interaction between warfarin and Lycium barbarum L.
    Lam AY; Elmer GW; Mohutsky MA
    Ann Pharmacother; 2001 Oct; 35(10):1199-201. PubMed ID: 11675844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variations in prothrombin time-international normalized ratio caused by drug-drug interaction in patients receiving warfarin: A retrospective observational study.
    Shiraishi C; Hirai T; Fujita S; Dohi K; Iwamoto T
    Int J Clin Pharmacol Ther; 2023 Apr; 61(4):139-147. PubMed ID: 36633369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.
    Linder MW; Looney S; Adams JE; Johnson N; Antonino-Green D; Lacefield N; Bukaveckas BL; Valdes R
    J Thromb Thrombolysis; 2002 Dec; 14(3):227-32. PubMed ID: 12913403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese.
    Chern HD; Ueng TH; Fu YP; Cheng CW
    Clin Chim Acta; 2006 May; 367(1-2):108-13. PubMed ID: 16413010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Warfarin dose related to apolipoprotein E (APOE) genotype.
    Kohnke H; Sörlin K; Granath G; Wadelius M
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):381-8. PubMed ID: 15952022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
    Ellis DJ; Usman MH; Milner PG; Canafax DM; Ezekowitz MD
    Circulation; 2009 Sep; 120(12):1029-35, 2 p following 1035. PubMed ID: 19738136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication.
    Malhi H; Atac B; Daly AK; Gupta S
    Postgrad Med J; 2004 Feb; 80(940):107-9. PubMed ID: 14970301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probable interaction between warfarin and torsemide.
    Bird J; Carmona C
    Ann Pharmacother; 2008 Dec; 42(12):1893-8. PubMed ID: 19017829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Major bleeding caused by warfarin in a genetically susceptible patient.
    Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y
    Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis.
    Lee JE; Ryu DH; Jeong HJ; Kim JH; Jun JE; Kim JS; Lee SY
    J Korean Med Sci; 2014 Sep; 29(9):1317-9. PubMed ID: 25246753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial.
    Makar-Aušperger K; Krželj K; Lovrić Benčić M; Radačić Aumiler M; Erdeljić Turk V; Božina N
    Ther Drug Monit; 2018 Jun; 40(3):362-368. PubMed ID: 29494423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.